LSU Biomedical Research Center: Semaglutide Delivers 20 Percent Reduction in Major Adverse Cardiovascular Events in Patients With Obesity But No History of Diabetes
November 13, 2023
November 13, 2023
BATON ROUGE, Louisiana, Nov. 13 (TNSres) -- The Louisiana State University's Pennington Biomedical Research Center issued the following news release:
* * *
Professor Emeritus Dr. Donna Ryan served as co-chair for steering committee behind revolutionary SELECT study, which identified cardiovascular benefits of Semaglutide for those without diabetes
* * *
Semaglutide, the antidiabetic medication that is also used to manage weight, has been shown . . .
* * *
Professor Emeritus Dr. Donna Ryan served as co-chair for steering committee behind revolutionary SELECT study, which identified cardiovascular benefits of Semaglutide for those without diabetes
* * *
Semaglutide, the antidiabetic medication that is also used to manage weight, has been shown . . .